Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.
OBJECTIVE
Recent clinical, randomized and observational studies showed that eribulin, an analogous of Halichondrin B, was beneficial and well-tolerated in heavily pretreated metastatic breast cancer patients. Here, we aim to evaluate the effectiveness and safety of eribulin in taxane-refractory metastatic breast cancer patients.


METHODS
In this subanalysis of the ESEMPIO study database, we selected 91 subjects with well-defined taxane refractoriness and complete data available.


RESULTS
41 patients (45.2%) showed clinical benefit; one complete response (2.2%) and 16 partial responses (17.6%) were observed. Median progression-free survival and median overall survival were 3.1 and 11.6 months, respectively. The most experienced adverse event was asthenia/fatigue (58%), followed by neutropenia (30%). The treatment-related toxicity led to eribulin-dose reduction in 19 patients and suspension in nine.


CONCLUSIONS
This study shows that eribulin is effective and well tolerated also in taxane-refractory patients in clinical practice.
UOC Oncologia Medica, Istituto Tumori Giovanni Paolo II, Bari, Italy.
Vito
V
Lorusso
Medical Oncology Division and Breast Unit, Ospedale A Perrino, Brindisi, Italy.
Saverio
S
Cinieri
UOC Oncologia Medica, Istituto Tumori Giovanni Paolo II, Bari, Italy.
Agnese
A
Latorre
Oncology Department, IRRCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
Luca
L
Porcu
Department of Medical Oncology, IRCCS AOU San Martino - IST, Genova, Italy.
Lucia
L
Del Mastro
Oncology Department, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy.
Fabio
F
Puglisi
Oncology Unit, Oncology Department, ASST Bergamo Ovest Ospedale, Treviglio, Bergamo, Italy.
Sandro
S
Barni
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D005500:Follow-Up Studies; D005663:Furans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D019233:Retreatment; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D000095662:Polyether Polyketides
D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D005663:Furans; D007659:Ketones; D043823:Taxoids; C080625:taxane; C490954:eribulin; D000095662:Polyether Polyketides
eribulin; metastatic breast cancer; taxane-refractory